Guidance for Corcept Therapeutics (CORT)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $0.95B – 1.05B | $0.93B | = Maintained | Details |
| 2026 | N/A | N/A | $0.90B – 1.00B | $0.96B | = Maintained | Details |
| 2025 | N/A | N/A | $800.00M – 850.00M | $852.70M | = Maintained | Details |
| 2025 | N/A | N/A | $850.00M – 900.00M | $899.00M | = Maintained | Details |
| 2025 | N/A | N/A | $900.00M – 950.00M | $905.40M | = Maintained | Details |
| 2025 | N/A | N/A | $900.00M – 950.00M | $855.10M | = Maintained | Details |
| 2024 | N/A | N/A | $675.00M – 700.00M | $661.10M | = Maintained | Details |
| 2024 | N/A | N/A | $620.00M – 650.00M | $610.60M | = Maintained | Details |
| 2022 | N/A | N/A | $400.00M – 430.00M | $414.40M | = Maintained | Details |
| 2021 | N/A | N/A | $365.00M – 375.00M | $371.00M | = Maintained | Details |
| 2020 | N/A | N/A | $355.00M – 365.00M | $366.22M | = Maintained | Details |
| 2020 | N/A | N/A | $355.00M – 375.00M | N/A | = Maintained | Details |
| 2020 | N/A | N/A | $355.00M – 375.00M | $363.79M | = Maintained | Details |
| 2019 | N/A | N/A | $285.00M – 315.00M | $298.30M | = Maintained | Details |
| 2018 | N/A | N/A | $250.00M – 270.00M | $291.40M |  Lowered |
Details |
| 2018 | N/A | N/A | $275.00M – 300.00M | N/A | = Maintained | Details |
| Q2 2018 | N/A | N/A | $275.00M – 300.00M | $290.20M | = Maintained | Details |
| 2017 | N/A | N/A | $157.00M – 162.00M | N/A | = Maintained | Details |
| 2017 | N/A | N/A | $125.00M – 135.00M | $124.00M | = Maintained | Details |
| 2017 | N/A | N/A | $115.00M – 125.00M | N/A | = Maintained | Details |
| Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| 2016 | N/A | N/A | $76.00M – 81.00M | $83.30M | = Maintained | Details |
| Q4 2016 | N/A | N/A | $79.00M – 82.00M | $80.30M | = Maintained | Details |
